Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Silver sulfadiazine is a topical sulfonamide antibiotic used primarily to prevent and treat wound infections in patients with second- and third-degree burns. It acts by releasing silver ions that bind to bacterial proteins and cell membranes, causing protein denaturation and cell death. The sulfadiazine component inhibits bacterial dihydropteroate synthase, interfering with folic acid synthesis essential for bacterial growth. Silver sulfadiazine is applied as a cream directly to the affected area. It is approved for use in burn care but may also be prescribed off-label for other skin infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on silver sulfadiazine.